Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration
The purpose of this study is to compare 12-month results of two single initial treatments—photodynamic therapy with verteporfin alone and this therapy combined with intravitreal bevacizumab—for neovascular age-related macular degeneration, not including patients with polypoidal choroidal vasculopathy who were presumed to have age-related macular degeneration.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Verteporfin Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Neovascular Age-related Macular Degeneration|
- Visual acuity [ Time Frame: The comparison between baseline and 12-month ] [ Designated as safety issue: No ]
|Study Start Date:||October 2006|
|Study Completion Date:||May 2008|
|Primary Completion Date:||May 2008 (Final data collection date for primary outcome measure)|
A single intravitreal injection of 1.25 mg of bevacizumab (0.05 mL of solution prepared from Avastin, 100 mg/4 mL vial) was performed within 2 weeks after PDT treatment.
Other Name: Avastin
|Department of Ophthalmology and Visual Science, Graduate School of Medical Sciences, Kumamoto University|
|1-1-1 Honjo, Kumamoto, Kumamoto, Japan, 860-8556|
|Principal Investigator:||Takahiro Kawaji, MD, PhD||Department of Ophthalmology, Kumamoto University Graduate School & Medical Sciences|